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Langerhans cells (LCs) are antigen-presenting cells that reside in the skin. They
uniquely express high levels of the C-type lectin receptor Langerin (CD207), which is
an attractive target for antigen delivery in immunotherapeutic vaccination strategies
against cancer. We here assess a library of 20 synthetic, well-defined mannoside
clusters, built up from one, two, and three of six monomannosides, dimannosides,
or trimannosides, appended to an oligopeptide backbone, for binding with Langerin
using surface plasmon resonance and flow cytometric quantification. It is found that
Langerin binding affinity increases with increasing number of mannosides. Hexavalent
presentation of the mannosides resulted in binding affinities ranging from 3 to 12 µM.
Trivalent presentation of the dimannosides and trimannosides led to Langerin affinity
in the same range. The model melanoma gp100 antigenic peptide was subsequently
equipped with a hexavalent cluster of the dimannosides and trimannosides as targeting
moieties. Surprisingly, although the bifunctional conjugates were taken up in LCs in
a Langerin-dependent manner, limited antigen presentation to cytotoxic T cells was
observed. These results indicate that targeting glycan moieties on immunotherapeutic
vaccines should not only be validated for target binding, but also on the continued
effects on biology, such as antigen presentation to both CD8+ and CD4+ T cells.
Keywords: mannoside, tumor associated antigens, peptide conjugate, vaccine model, glyco-antigen, Langerhans
cell, dendritc cell, langerin
INTRODUCTION
Immunotherapeutic vaccination is an appealing approach to direct the immune response toward
specific tumor cells. The human skin is an obvious vaccination site for antitumor therapies. Multiple
antigen-presenting cell (APC) populations, including Langerhans cells (LCs), CD14+ dermal
dendritic cells (dDCs), and CD1a+ dDCs, are present in the different layers of the skin, where they
are key players in the activation of the adaptive immune response. The precise role and the antigen
cross-presenting capacity of the different populations remains controversial. In this brief report,
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we set out to investigate LCs that reside in the epidermis.
Langerhans cells, representing 1–5% of the epidermal cells, are
considered to be large contributors to in vivo antigen cross-
priming, compared to other efficient cross-presenting APCs, such
as CD141+ DCs, which are less prevalent in the skin (Haniffa
et al., 2012; Nierkens et al., 2013; Levin et al., 2015). Langerhans
cells furthermore play a key role in the induction of TH1 and
TH17 responses by antigen-specific CD4+ T cells (Zaric et al.,
2015). Depletion of LCs highly affected therapeutic epicutaneous
immunization against cancer cells and reduced the protection by
the immune system against tumor growth (Stoitzner et al., 2008).
Langerhans cells specifically express the C-type lectin receptor
(CLR) Langerin (CD207) (Santegoets et al., 2008), which is
a pattern recognition receptor (PRR), binding carbohydrate
structures such as LewisY antigens and oligomannosides
(Feinberg et al., 2011). The Langerin receptor has been targeted
for its endocytic and immunomodulatory properties. Liposome
functionalization with heparin-derived monosaccharide analogs
enhanced Langerin-mediated endocytosis (Wamhoff et al., 2019).
By targeted delivery with antibody conjugates, humoral immune
responses could be induced, quantified by B-cell activation and
antibody isotype switching, as well as promotion of T-follicular
helper cell proliferation for B-cell support (Yao et al., 2015;
Bouteau et al., 2019). Enhanced antigen presentation to CD8+
and CD4+ T cells could also be established, which is necessary for
T cell-mediated tumor killing in vaccination strategies (Idoyaga
et al., 2008). Langerin targeting could also be established with
fucosylated synthetic long peptide antigens, which resulted in
enhanced antigen presentation by LCs and cross-presentation
(Fehres et al., 2017). The exploitation of mannosides for targeting
Langerin has been minimally explored due to the presence of
many other mannose-binding CLRs, including DC-SIGN (Holla
and Skerra, 2011; Varga et al., 2013; Medve et al., 2018).
To identify the optimal oligomannoside structure for
Langerin targeting, we have used a library of 20 mannose
ligands, which we have previously assessed for DC-SIGN
binding. The library is built up from clusters of mannosides,
appended to a peptide backbone. Five (oligo)mannoside
structures (Man; Manα1,2Man; Manα1,3Man; Manα1,6Man;
and Manα1,3Man1,6Man saccharides), each representing a
substructure of the high affinity Man9 oligosaccharide, were used
to build the library. The library members systematically vary in
saccharide structure (coded A–E) and number of copies on the
peptide scaffold (n = 1, 2, 3, 6, Figure 1A, and Supplementary
Figure 1) (Li et al., 2019).
RESULTS AND DISCUSSION
To determine Langerin extracellular domain (ECD) binding
affinity, we measured interactions with surface plasmon
resonance (SPR) assays. On the cell surface, Langerin
oligomerizes into a trimer for high-affinity ligand engagement
(Feinberg et al., 2010). Therefore, in the SPR assays, we made
use of a trimeric Langerin ECD attached on the surfaces by
the N-termini of their Neck domain, to mimic the natural
presentation of the carbohydrate recognition domains at the
cell membrane (Feinberg et al., 2011; Porkolab et al., 2020).
In the direct interaction mode, where the Langerin ECD was
bound to the sensor chip surface facing the ligands in the solvent,
the apparent Kd was calculated for the ligands. Hexavalent
presentation of the saccharides corresponded to binding affinities
in a 3- to 12-µM range, which is sufficient for Langerin targeting
purposes (Table 1). The affinity of the Manα1,6Man glycan D6
was approximately fourfold lower than to the other hexavalent
dimannosides (12.3 µM for D6, vs. 3.2 µM for B6 and 3.9 µM
for C6), suggesting that Langerin is able to differentiate between
the dimannoside structures. This finding is consistent with
crystallographic analysis where Manα1,2Man and Manα1,3Man
were found binding to the monomeric Langerin CRD, revealing
preferential binding of these disaccharides to Langerin (Feinberg
et al., 2011). Surprisingly, a minimal affinity difference was
observed between the trivalent and hexavalent presentation
of the same Manα1,6Man glycan (from 9.8 to 12.3 µM). The
same phenomenon was seen with the Manα1,3Manα1,6Man E6
(from 6.5 to 4.23 µM), while the binding affinity of saccharides
A and B improved by at least 13-fold from the trivalent to the
hexavalent presentation. To quantify binding of the low-affinity
ligands, IC50 values were assessed with a competition assay using
the same trimeric Langerin ECD. Langerin affinity decreased
with lower numbers of mannoside copies. Of the monovalent
saccharides, only B1 had a binding affinity in the mM range,
indicating that the affinity of the other mannosides for Langerin
is too weak to be determined in this assay.
We continued to validate cluster binding on Langerin+
cells, using a Langerin-expressing human Epstein–Barr virus-
transformed B-lymphoblastic cell (BLC) line (Supplementary
Figure 2A; van der Vlist et al., 2011). The cells were pulsed
with biotin-functionalized clusters (indicated with lowercase
letter codes in Figure 2A) for 30 min at 4◦C before staining
with fluorescent-labeled streptavidin and flow cytometric
quantification. The clusters presenting three or six copies of the
Man, Manα1,2Man, and Manα1,3Man saccharides (a3, a6, b3,
b6, c3, and c6) showed significantly increased Langerin binding
compared to the unstimulated control (Figure 2A), in line with
the SPR assay. For the Manα1,6Man and trimannosides, the
binding of the trivalent clusters (d3 and e3) was very similar
to the binding of the corresponding hexavalent constructs (d6
and e6), as observed in SPR assays. Binding of the clusters
could be blocked using a Langerin-specific antibody, confirming
Langerin binding specificity of the mannosylated clusters.
Taken together, the findings of the binding assays indicate that
Langerin affinity depends on the nature of the oligomannosides
and that it can be improved through multivalency. Overall,
the hexavalent presentation of the mannoside provided ligands
with high Langerin affinity. The uptake of these ligands by
the Langerin+ BLCs was therefore investigated (Figure 2B).
The biotin-functionalized clusters were bound for 60 min at
4◦C, where after the unbound ligands were washed away with
precooled (4◦C) medium. The uptake process was initiated by
adding warm (37◦C) medium to the cells. Cells were sampled
on the indicated time points and put on ice to inhibit the
uptake processes. The loss of hexavalent clusters on the cell
membrane was quantified via flow cytometry after staining
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FIGURE 1 | Cartoon of the mannoside clusters. (A) A schematic overview of the 20 mannoside clusters. (B) Only the hexavalent clusters are further conjugated to a
gp100 antigen.
TABLE 1 | Binding affinity to the Langerin receptor.
Ligand IC50 (µM) Kdapp (µM) Ligand IC50 (µM) Kdapp (µM)
A1 N.D. D1 N.D.
A2 2424 ± 30 D2 16
A3 43 D3 9.8
A6 3.4 ± 1.4 D6 12.3 ± 0.7
B1 4,138 ± 733 E1 N.D.
B2 181 ± 4 E2 278
B3 48 E3 4.23
B6 3.2 ± 1.7 E6 6.5 ± 2.7
C1 N.D. N.D. Not Determined
C2 1,416 ± 13
C3 281 ± 14
C6 3.9 ± 1.5
Surface plasmon resonance (SPR) analysis demonstrates increase in Langerin affinity with increased multivalency (n = 1 > 2 > 3 > 6). All hexavalent clusters bind within
an approximate 10 µM range.
with a fluorophore-conjugated streptavidin. Approximately 35–
55% of the clusters were internalized after 60 min. Blocking the
Langerin receptor or inhibition of receptor-mediated endocytosis
by fixing the cells under gentle conditions prevented the loss of
the signal (Figure 2B, Supplementary Figure 2C). Targeting
of the mannosylated clusters to Langerin thus also triggers
Langerin-mediated internalization of the ligands, encouraging
the application of these constructs for in vivo targeting of the
Langerin receptor.
Previously, it has been demonstrated that LewisY -
functionalized peptides can be used as vaccine modalities
targeting Langerin for enhanced antigen presentation (Fehres
et al., 2015). We therefore explored whether the appendage
of the mannose clusters to a tumor-associated antigen could
have a similar effect. We selected the melanoma-associated
gp100 antigen as a well-known tumor-associated model
antigen. As previously described, azidolysine-functionalized
gp100280−288+44−59 antigens were synthesized using automated
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FIGURE 2 | The binding, internalization, and antigen presentation profiles of the mannoside clusters. (A) Binding of biotin-functionalized clusters to Langerin+ BLCs
was measured by flow cytometry. Normalized to medium, the binding profiles mirror the SPR data, where higher multivalent presentation of the saccharides
significantly increases the receptor binding compared to medium. The binding is inhibited by blocking with a Langerin-binding antibody. (B) Internalization of the
biotin-functionalized clusters by Langerin+ BLCs was measured by flow cytometry. Internalization was normalized to the unstimulated control. One experiment is
shown as representative of three individual experiments. b6, d6, and e6 are internalized after 30 min, whereas c6 remained longer at the surface. Blocking the
Langerin receptor prevents the loss from the membrane. (C) Antigen presentation by the Langerin+ BLCs was measured by IFNγ release of activated T cells.
Mannosylated antigens are not presented. Low levels of E6-gp100 activated T cells could be measured, although at lower levels than for the gp100 control. Data are
representative of three independent experiments with gp100280-288 as positive control and are represented as average ± SD, N.D., not determined. (D) Antigen
presentation by the MUTZLCs was measured by IFNγ release of activated T cells. Mannosylation of the gp100 antigen significantly reduced antigen presentation
compared to the gp100 control. *p < 0.05, **p < 0.01, and ***p < 0.001.
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Fmoc-based solid phase peptide synthesis and conjugated to
propargyl-functionalized B6, C6, D6, E6 clusters to generate
bifunctional mannosylated antigens (Figure 1B; Li et al., 2019).
Four natural occurring amino acids gp100276−279 were used as
spacer between the two moieties.
Pathogen encounter in the skin causes the LCs to undergo
genetic reprogramming. The cell focus shifts from endocytosis
to efficient antigen processing and presentation, along with
altered cytokine secretion for naive T cell priming and cell
migration toward the lymphoid organs (Banchereau et al., 2012;
Polak et al., 2014). To study the capacity of the bifunctional
conjugates to induce antigen presentation, we quantified T cell
activation. A gp100280−288 peptide-specific CD8+ T cell clone
was used in this assay, which secretes interferon γ (IFNγ)
upon interaction with the APC-presented gp100 antigen. The
BLCs were stimulated for 30 min with the conjugates, where
after the compounds were washed away. After overnight
stimulation with the T cells, the secreted IFNγ in the medium
was measured through enzyme-linked immunosorbent assay
(ELISA). The gp100280−288 short peptide was used as positive
control for antigen recognition by CD8+ T cells in major
histocompatibility complex (MHC-I) molecules. Surprisingly,
minimal T cell activation was measured upon stimulation with
the mannosylated antigens, whereas the use of the gp100 peptide
as stand-alone antigen was able to induce activation (Figure 2C).
To probe antigen presentation induction by the bifunctional
conjugates in a different model, we employed in vitro-
generated human MUTZ-3 cell line-derived LCs (MUTZ-LCs).
The MUTZ-LCs are an established Langerin-expressing model
and demonstrate relatively similar binding and internalization
kinetics as the Langerin+ BLCs (Supplementary Figures 2A,C–
E) to study pathogen interactions with, for example, HIV (de
Jong et al., 2010; Czubala et al., 2016). After 30-min stimulation
with the mannosylated antigens, the MUTZ-LCs were washed
and cocultured with the gp100280−288-restricted T cell clone,
after which T cell activation was measured as described above.
In this setup, we were able to measure T cell activation by
the bifunctional conjugates (Figure 2D); however, antigen
presentation with all mannosylated conjugates was significantly
lower than the unglycosylated gp100 antigen, in line with the
results obtained in the BLC assay.
These results stand in contrast to previous reports that have
demonstrated that Langerin-mediated internalization of LewisY -
glycosylated peptide antigens leads to enhanced antigen cross-
presentation by human LCs (Fehres et al., 2017; Duinkerken
et al., 2019). On the other hand, it has been shown that LCs
are not capable of presenting measles virus (MV) and HIV-1
antigens to cytotoxic CD8+ T cells (van der Vlist et al., 2011;
van den Berg et al., 2015). The glycoproteins decorating the viral
envelope of these pathogens are decorated with oligomannosides
(Hashiguchi et al., 2007; Bonomelli et al., 2011). Internalization
and processing of mannosylated antigens via Langerin may
therefore deviate from the uptake and processing of Lewis-
antigen conjugates. It is known that, upon Langerin capture,
antigens are endocytosed into Birbeck granules, resulting in
antigen degradation. Birbeck granules are rod-like structures
that are specific to LCs, and they form a component of the
endosomal recycling compartment (Thépaut et al., 2009). It
has been shown that Langerin-endocytosed HIV antigens are
trafficked to Birbeck granules and rapidly degraded (de Witte
et al., 2007). This clearance of the virus by Langerin-mediated
internalization efficiently prevents HIV-1 and MV transmission
to T cells (de Witte et al., 2007; van der Vlist et al., 2011).
The mannosylated antigens, under study here, could undergo
the same fate, resulting in degradation and minimal antigen
presentation and T cell activation as observed here. In contrast,
LewisY -functionalized peptides are properly loaded onto MHC-I
and cross-presented effectively CD8+ T cells (Fehres et al., 2017).
Furthermore, whether only one LewisY moiety was present on the
synthetic long peptides, or whether a multivalent LewisY -antigen
construct was offered to LCs, enhanced cross-presentation was
achieved (Fehres et al., 2017; Duinkerken et al., 2019). These
data suggest the involvement of LewisY -mediated routing for
successful MHC-I loading and antigen cross-presentation. It
thus seems that the nature of the targeting glycan decides the
immunological outcome (Geijtenbeek and Gringhuis, 2016).
We have previously described that the mannosylated antigens
studied here can be targeted to APCs expressing DC-SIGN, which
led to improved antigen uptake. The results obtained with LCs
described here indicate that, in an in vivo setting, antigen capture
by Langerin can contribute to clearance of the conjugate, thereby
necessitating the use of a higher vaccine dosage to obtain an
adequate cytotoxic CD8+ T cell response.
CONCLUSION
In summary, we have described the evaluation of a library
of oligomannoside clusters for binding to Langerin. In line
with previous results, our study has shown an increase in
affinity for the lectin with higher multivalent presentation of
the mannoside saccharides. Micromolar binding affinity for
the hexavalent compounds was measured, as well as Langerin-
mediated uptake, demonstrating their applicability as a Langerin-
targeting device. Nonetheless, conjugation of the hexavalent
mannoside clusters to the gp100 antigen significantly reduced
antigen cross-presentation to CD8+ T cells in two independent
Langerin+ APC models, indicating that higher CLR receptor
affinity does not have to lead to improved antigen presentation,
as we have also observed with DC-SIGN targeting in earlier work
(Li et al., 2019). Nevertheless, antigen processing after Langerin-
mediated endocytosis and priming of CD4+ T cells could provide
a different path to boost the immune response. Further work is
required to establish whether antigen presentation to CD4+ T
cells is indeed enhanced, as seen with MV (van der Vlist et al.,
2011). Literature implicates the importance of glycan moiety
choice for Langerin targeting, as LewisY -functionalized antigens
did achieve enhanced Langerin-mediated antigen presentation to
cytotoxic T cells (Fehres et al., 2017; Duinkerken et al., 2019).
The results presented here emphasize the need to validate the
glycan moiety in conjugates not only for receptor binding, but
also downstream biological effects, such as antigen presentation
to CD8+ and CD4+ T cells, effectuated by different cell types,
before they can be implemented as immunotherapeutic vaccine.
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MATERIALS AND METHODS
General Synthesis of the Library
The synthesis of the mannoside library has been described in full
in earlier work (Li et al., 2019).
Cell Culture
Langerin expressing Epstein–Barr virus-transformed BLCs were
used as autologous APC (van der Vlist et al., 2011) and were
cultured in RPMI 1640 (InvitrogenTM) supplemented with 10%
fetal calf serum (Biowittaker), 1% penicillin, and streptomycin
(both Lonza). Langerin-expressing MUTZ-3-derived LCs were
differentiated from the MUTZ-3 progenitor cell line with
100 ng/mL granulocyte-macrophage colony-stimulating factor
(Biosource), 10 ng/mL transforming growth factor β (R&D
Systems), and 2.5 ng/mL tumor necrosis factor α (Miltenyi)
(de Jong et al., 2010).
Surface Plasmon Resonance Analysis
The ECD of Langerin (residues 68–328) was overexpressed and
purified as previously described (Thépaut et al., 2009). The SPR
competition experiments were performed on a Biacore T200
using a CM3 series S sensor chip. Control flow cell 1 was
functionalized with bovine serum albumin (BSA), whereas flow
cell 2 and 3 were treated with 60 µg/mL BSA-Man α1-3[Manα1-
6]Man (Dextra) in 10 mM NaOAc pH4 (final densities 2.062
and 2.183 RU, respectively). All flow cells were blocked with
ethanolamine. The affinities for the Langerin ECD were evaluated
via an inhibition assay, using 25 mM Tris-HCl pH 8, 150 mM
NaCl, 4 mM CaCl2, and 0.05% P20 surfactant as running buffer.
Langerin ECD (20 µM) was injected at 5 µL/min, with or without
inhibitor at increasing concentrations. The data were analyzed in
Biacore BIAevaluation software using four parameter equation,
and the IC50 was determined.
To determine the apparent Kd value, direct interaction
experiments were executed on a T200 Biacore with a CM3 series
S sensor chip. The Langerin ECD in this assay was functionalized
with a StreptagII on the N-terminus (Langerin S-ECD), for
oriented capture on the sensor chip surface. The flow cells
were functionalized with streptactin protein after EDC/NHS
activation. Control flow cell 1 was functionalized with BSA,
whereas another flow cell was functionalized with 100 µg/mL
Langerin S-ECD via tag-specific capture and simultaneous
amine coupling as previously described (Porkolab et al., 2020).
An approximate density of about 2.609 RU was achieved on
the chip surface. The compounds were injected in increasing
concentrations with a flow rate of 30 µL/min in the previously
mentioned running buffer. The data were analyzed in Biacore
BIAevaluation software for direct interaction 1:1 calculation to
determine the apparent Kd value.
Mannose Library Binding
Approximately 105 cells were washed and resuspended in 100 µL
precooled (4◦C) 1 × Hanks balanced salt solution (HBSS;
Gibco), supplemented with 1% BSA. The cells were preincubated
with 20 µg/mL anti-CD207 [clone 10E2, in-house (de Witte
et al., 2007)] in the blocking conditions for 45 min on ice;
10 µM of biotin-functionalized clusters or 1 µg/mL of biotin-
functionalized LewisY - or mannose-conjugated polyacrylamide
as control was added. After 30-min incubation on ice, the cells
were washed with precooled (4◦C) phosphate-buffered saline
(PBS) and stained with Alexa647-streptavidin (Invitrogen) in
PBS supplemented with 0.5% BSA and 0.02% NaN3. The cells
were extensively washed after 30-min incubation on ice and
fixed in PBS supplemented with 0.5% paraformaldehyde (PFA).
Fluorescence was measured by flow cytometry (CyAnTM APD
with SummitTM software) and analyzed using FlowJo v10.
Internalization Assay
The cells were harvested and washed with cold (4◦C) HBSS,
before preincubation with 20 µg/mL anti-CD207 [clone 10E2, in-
house (de Witte et al., 2007)] for 45 min on ice in the blocking
condition, with 1% PFA in PBS for 20 min on room temperature
(RT) in the gently fixated condition, or without pretreatment;
20 µM of the hexavalent biotinylated mannosides was added to
the cells in cold HBSS and incubated for 1 h at 4◦C. The unbound
clusters were washed away with cold HBSS. Warm (37◦C) HBSS
was added to the cells followed by incubation at 37◦C in a shaking
heating block. At the indicated time points, a sample was taken
and put on ice. The cells were then stained with streptavidin-
Alexa647 (Thermo Fisher), and the fluorescence was quantified
with flow cytometric analysis (CyAnTM APD with SummitTM
software) and analyzed with FlowJo v10.
Antigen Presentation
Cells were seeded at 50 × 103 cells/well in a 96-well
plate (Greiner) and incubated with 20 µM of the peptide
conjugates (Supplementary Figure 2F). The gp100 short peptide
(gp100280−288) was taken along as a positive control. After 30 min
of stimulation, cells were washed and cocultured with 105 CD8+
HLA-A2.1 restricted T cells from a clone transduced with a
gp100280−288 specific TCR (Schaft et al., 2003). After overnight
stimulation, IFNγ levels in the supernatant were measured by
ELISA according to manufacturer’s protocol (Biosource) and
measured at 450 nm on the iMarkTM Microplate Absorbance
Reader (Bio-Rad).
Statistics
The data are presented as the mean ± SD of at least three
independent experiments. Statistical analysis was performed in
GraphPad Prism v8. Statistical significance was set at P < 0.05
and was evaluated by the Mann–Whitney U test.
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